A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8⁺ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma

References

• Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–8. doi:10.1016/S2468-1253(17)30074-2.
   PubMed Web of Science ®Google Scholar
• Galon J, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Galon J, Lanzi A. Immunoscore and its introduction in clinical practice. Q J Nucl Med Mol Imaging. 2020;64(2):152–161. doi:10.23736/S1824-4785.20.03249-5.
   PubMed Web of Science ®Google Scholar
• Marliot F, Chen X, Kirilovsky A, Sbarrato T, El Sissy C, Batista L, Van den Eynde M, Haicheur-Adjouri N, Anitei M-G, Musina A-M, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J ImmunoTher Cancer. 2020;8:(1). doi:10.1136/jitc-2019-000272.
   PubMed Web of Science ®Google Scholar
• Pagès F, International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman W-H, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618. doi:10.1200/JCO.2010.30.5425.
   PubMed Web of Science ®Google Scholar
• El Sissy C, Kirilovsky A, Van den Eynde M, Muşină A-M, Anitei M-G, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26(19):5198–5207. doi:10.1158/1078-0432.CCR-20-0337.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lou Y, Zhu X, Wang YC, Zhang L, Liu HL. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer. Biosci Rep. 2019:39(3). doi:10.1042/BSR20190003
   Google Scholar
• Xu Y, Lou X, Liang Y, Zhang S, Yang S, Chen Q, Xu Z, Zhao M, Li Z, Zhao K, et al. Predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer using tumor-infiltrating lymphocytes density. . 2021;14:5891–5899. doi:10.2147/JIR.S342214.
   Google Scholar
• Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 2011;6:49. doi:10.1186/1748-717X-6-49.
   PubMed Web of Science ®Google Scholar
• Farchoukh L, Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma. Mod Pathol. 2021;34(1):171–183.
   PubMed Web of Science ®Google Scholar
• McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 2017;8(12):19803–19813. doi:10.18632/oncotarget.15048
   PubMedGoogle Scholar
• Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat Rev Immunol. 2018;18(8):527–535. doi:10.1038/s41577-018-0009-3.
   PubMed Web of Science ®Google Scholar
• Jarosch A, Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. Oncoimmunology. 2018;7(2):e1393133. doi:10.1080/2162402X.2017.1393133.
   PubMed Web of Science ®Google Scholar
• Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126(7):2404–2411. doi:10.1172/JCI86892.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li X-D, Mauceri H, Beckett M, Darga T, et al. STING-Dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in Immunogenic tumors. Immunity. 2014;41(5):843–852. doi:10.1016/j.immuni.2014.10.019
   PubMed Web of Science ®Google Scholar
• Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152. doi:10.1186/s12943-019-1087-y.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Davis D, Yuan H, Yang Y-M, Liang F-X, Sehgal PB. Interferon-α-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells. Współczesna Onkologia. 2018;22(2):86–94. doi:10.5114/wo.2018.76149.
   Google Scholar
• Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, Casanova J-L, Haller O, Kochs G. Induction of MxA gene expression by influenza a virus requires type I or type III interferon signaling. J Virol. 2007;81(14):7776–7785. doi:10.1128/JVI.00546-06.
   PubMed Web of Science ®Google Scholar
• Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res: The Official J Int Soc Interferon Cytokine Res. 2011;31:79–87.
   PubMed Web of Science ®Google Scholar
• Bond E, Liang F, Sandgren KJ, Smed-Sörensen A, Bergman P, Brighenti S, Adams WC, Betemariam SA, Rangaka MX, Lange C, et al. Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations. J Invest Dermatol. 2012;132(1):114–123. doi:10.1038/jid.2011.246.
   PubMed Web of Science ®Google Scholar
• Ma R, Yuan D, Guo Y, Yan R, Li K. Immune effects of γδ T cells in colorectal cancer: a review. Front Immunol. 2020;11:1600. doi:10.3389/fimmu.2020.01600.
   PubMed Web of Science ®Google Scholar
• Hammarström K, Imam I, Mezheyeuski A, Ekström J, Sjöblom T, Glimelius B. A comprehensive evaluation of associations between routinely Collected Staging Information and the Response to (Chemo)radiotherapy in Rectal Cancer. Cancers (Basel). 2020;13(1). doi:10.3390/cancers13010016.
   PubMed Web of Science ®Google Scholar
• Liang F, Nilsson LM, Byvald F, Rezapour A, Taflin H, Nilsson JA, Yrlid U. A fraction of CD8+ T cells from colorectal liver metastases preferentially repopulate autologous patient-derived xenograft tumors as tissue-resident memory T cells. Cancers (Basel). 2022;14:14(12). doi:10.3390/cancers14122882.
   Web of Science ®Google Scholar
• Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2018;472(2):175–186.10.1007/s00428-017-2232-x
   PubMed Web of Science ®Google Scholar
• Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015;11(4):e1004782.10.1371/journal.ppat.1004782
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi:10.1200/JCO.2009.23.7370.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im Y-H, Nam SJ, Kim SW, Lee JE, Yu J-H, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173(2):255–266. doi:10.1007/s10549-018-4981-x
   PubMed Web of Science ®Google Scholar
• Yang Y, Tian W, Su L, Li P, Gong X, Shi L, Zhang Q, Zhao B, Zhao H. Tumor-infiltrating cytotoxic T cells and tumor-associated macrophages correlate with the outcomes of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Front Oncol. 2021;11:743540. doi:10.3389/fonc.2021.743540.
   PubMed Web of Science ®Google Scholar
• Zaghloul H, Abbas A, Abdulah D. Tumor microenvironment mediators CD8(+)- and FOXP3(+)-labeled T lymphocytes are prospective prognosticators in curatively treated rectal cancer patients. J Gastrointest Cancer. 2021;52(1):177–186. doi:10.1007/s12029-020-00376-1.
   PubMed Web of Science ®Google Scholar
• Shinto E, Omata J, Sikina A, Sekizawa A, Kajiwara Y, Hayashi K, Hashiguchi Y, Hase K, Ueno H. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer. BJS Open. 2020;4(2):301–309.10.1002/bjs5.50251
   PubMed Web of Science ®Google Scholar
• Lai S, Lou X, Fan X, Sun W, Deng Y, Wang J, Huang Y, Dou R. Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy. Gastroenterol Rep (Oxf). 2020;8(6):445–452. doi:10.1093/gastro/goaa016.
   PubMed Web of Science ®Google Scholar
• Miyakita H, Tumor-infiltrating lymphocytes in biopsy specimens obtained 7 days after starting chemoradiotherapy for rectal cancer are predictors of the response to chemoradiotherapy. Oncology. 2020;98(12):869–875. doi:10.1159/000508922.
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106(10):1381–1392. doi:10.1002/bjs.11179.
   PubMed Web of Science ®Google Scholar
• Li Y, Li G, Zhang J, Wu X, Chen X. The dual roles of human γδ T cells: anti-tumor or tumor-promoting. Front Immunol. 2020;11:619954. doi:10.3389/fimmu.2020.619954.
   PubMedGoogle Scholar
• Hu G, Wu P, Cheng P, Zhang Z, Wang Z, Yu X, Shao X, Wu D, Ye J, Zhang T, et al. Tumor-infiltrating CD39 + γ δ Tregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology. 2017;6(2):e1277305. doi:10.1080/2162402X.2016.1277305.
   PubMed Web of Science ®Google Scholar
• Rong L, Li K, Li R, Liu H-M, Sun R, Liu X-Y. Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. World J Gastroenterol. 2016;22(13):3573–3580. doi:10.3748/wjg.v22.i13.3573.
   PubMed Web of Science ®Google Scholar
• Lu C, Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J Immunother Cancer. 2019;7(1):157. doi:10.1186/s40425-019-0635-8.
   PubMedGoogle Scholar
• Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53(6):1215–1229.e8. doi:10.1016/j.immuni.2020.10.020
   PubMed Web of Science ®Google Scholar